15^th World Heart Congress

Precision cardiology continues to reshape cardiovascular care by tailoring treatments to a patient’s genetic, molecular, and lifestyle profile. Personalized therapeutic strategies are driven by advanced genomic sequencing, biomarker profiling, and AI-based predictive models that allow clinicians to identify individualized risk factors and disease patterns. This approach enhances treatment accuracy, reduces adverse effects, and improves long-term cardiac outcomes. Pharmacogenomics is increasingly guiding medication choices, while targeted therapies are being developed to address specific molecular pathways involved in heart disease. Integrating personalized rehabilitation plans, nutrition strategies, and digital health data further strengthens patient-centered care. As precision cardiology expands, it offers new avenues for early diagnosis, optimized drug response, and customized treatment plans that align with each patient’s biological makeup. The future holds immense potential as multi-omics technologies and advanced data analytics converge to deliver more effective, tailored solutions for cardiovascular prevention, intervention, and management, ultimately transforming traditional paradigms of heart care into highly individualized practices.

Preventive cardiology and lifestyle medicine prioritize early intervention, personalized risk assessment, and long-term wellness to reduce the global burden of cardiovascular disease. Modern prevention strategies integrate digital health monitoring, genetic risk evaluation, and biomarker profiling to identify individuals at heightened risk before symptoms appear. Lifestyle medicine focuses on clinically proven interventions such as nutrition optimization, physical activity, stress reduction, and sleep improvement to strengthen cardiovascular resilience. Behavioral coaching and digital platforms enhance patient engagement and adherence. Evidence-based guidelines emphasize early management of lipid disorders, obesity, diabetes, and hypertension to prevent progression to severe cardiac conditions. Community-based prevention programs and public health policies support widespread awareness and healthier environments. As preventive cardiology evolves, the emphasis shifts from treating disease to promoting holistic, long-term heart health through proactive, personalized, and sustainable lifestyle strategies that benefit individuals and communities.

Clinical cardiology focuses on the comprehensive evaluation, diagnosis, treatment, and long-term management of patients with cardiovascular diseases. It serves as the foundation of cardiovascular healthcare by integrating clinical examination, diagnostic investigations, risk assessment, and evidence-based therapeutic strategies to manage a wide range of cardiac disorders. Cardiologists are increasingly adopting advanced imaging modalities, cardiac biomarkers, genetic testing, and digital health technologies to improve diagnostic accuracy and personalize patient care. The growing burden of ischemic heart disease, heart failure, arrhythmias, valvular disorders, and cardio-metabolic diseases necessitates continuous education and the adoption of innovative clinical practices that improve quality of life while reducing cardiovascular morbidity and mortality.

This session will explore contemporary advances in clinical cardiology, including guideline-directed medical therapy, outpatient and inpatient cardiac care, multimodality imaging, preventive strategies, cardiovascular risk stratification, and management of complex cardiac conditions. Experts will present recent clinical research, real-world case studies, diagnostic innovations, and therapeutic developments that support optimal patient care across diverse healthcare settings. Discussions will emphasize multidisciplinary collaboration, personalized treatment planning, quality improvement initiatives, and integration of emerging technologies into routine clinical practice. The session provides an excellent platform for clinicians, researchers, trainees, and healthcare professionals to exchange knowledge and discuss the future of patient-centered cardiovascular medicine.

Advances in interventional cardiology continue to elevate precision, safety, and therapeutic success across a wide range of cardiovascular conditions. Innovations in stent technology, catheter-based procedures, and minimally invasive interventions allow effective treatment of complex coronary and structural heart diseases with reduced recovery times. Breakthroughs such as bioresorbable scaffolds, drug-eluting devices, and ultra-thin stents improve long-term vessel healing and reduce complication risks. Transcatheter interventions, including TAVR, TMVR, and left atrial appendage closure, offer life-saving alternatives for high-risk patients who are unsuitable for open-heart surgery. Enhanced imaging and navigation systems support real-time procedural accuracy, improving outcomes and procedural efficiency. Robotic assistance and AI-guided planning further enhance precision while minimizing operator fatigue. As techniques advance, interventional cardiology is expanding its role in preventive and corrective cardiovascular care, offering patients safer, faster, and more personalized treatment options. The ongoing evolution of devices, technologies, and techniques is setting new benchmarks in cardiovascular intervention and transforming modern heart care.

Heart failure remains one of the most significant global cardiovascular challenges, affecting millions of individuals and contributing substantially to healthcare utilization, hospital admissions, and mortality. Advances in pharmacological therapy, device-based treatment, precision diagnostics, and multidisciplinary heart failure management have significantly improved survival and quality of life for affected patients. Comprehensive heart failure care involves accurate diagnosis, optimization of guideline-directed medical therapy, remote monitoring, patient education, nutritional support, psychosocial care, and coordinated follow-up. Cardiac rehabilitation further enhances recovery through supervised exercise programs, lifestyle modification, risk factor management, and behavioral counseling, enabling patients to regain functional capacity while reducing recurrent cardiovascular events.

This session will present the latest developments in heart failure diagnosis, advanced pharmacotherapies, ventricular assist devices, remote patient monitoring, rehabilitation strategies, multidisciplinary care models, and innovative approaches to chronic disease management. Researchers and clinicians will discuss emerging clinical trials, personalized treatment pathways, exercise prescription, digital health solutions, and quality improvement initiatives that optimize long-term patient outcomes. The session will also explore evolving international guidelines, integrated rehabilitation programs, and future innovations designed to improve functional recovery, reduce hospital readmissions, and enhance the overall quality of life for patients living with heart failure.

Cardiac surgery remains one of the most advanced and rapidly evolving specialties in cardiovascular medicine, offering life-saving interventions for patients with complex heart diseases. Continuous innovations in surgical techniques, anesthesia, perioperative care, and minimally invasive procedures have significantly improved patient safety, reduced recovery times, and enhanced long-term clinical outcomes. Procedures such as coronary artery bypass grafting (CABG), valve repair and replacement, aortic surgery, congenital heart defect correction, and heart transplantation continue to evolve through the integration of robotic-assisted surgery, hybrid operating rooms, enhanced imaging technologies, and precision surgical planning. Modern cardiac surgery emphasizes multidisciplinary collaboration among surgeons, cardiologists, anesthesiologists, intensivists, and rehabilitation specialists to deliver comprehensive, patient-centered care.

This session will highlight recent advances in cardiac surgery, including minimally invasive and robotic-assisted procedures, complex valve surgery, aortic reconstruction, coronary revascularization, hybrid surgical interventions, perioperative management, and enhanced recovery protocols. Experts will present emerging surgical technologies, artificial intelligence-assisted planning, clinical outcomes, innovative biomaterials, and evidence-based approaches that improve surgical success and patient quality of life. Discussions will also address challenging surgical cases, postoperative complications, multidisciplinary heart teams, and future directions shaping cardiovascular surgery. The session provides an excellent platform for surgeons, clinicians, researchers, engineers, and healthcare professionals to exchange scientific knowledge and explore innovative solutions in modern cardiac surgery.

Cardiac electrophysiology is a specialized field dedicated to understanding, diagnosing, and treating abnormalities of the heart's electrical system. Cardiac arrhythmias, including atrial fibrillation, ventricular tachycardia, supraventricular tachycardia, and inherited rhythm disorders, remain major contributors to cardiovascular morbidity, stroke, heart failure, and sudden cardiac death. Advances in electrophysiological mapping, catheter ablation, implantable cardiac devices, remote rhythm monitoring, and artificial intelligence have transformed the management of complex arrhythmias. Precision diagnostics, improved risk stratification, and personalized therapeutic approaches are enabling clinicians to deliver safer and more effective rhythm management while minimizing complications and improving long-term patient outcomes.

This session will explore the latest innovations in cardiac electrophysiology, including three-dimensional electroanatomical mapping, catheter ablation technologies, implantable cardioverter-defibrillators (ICDs), pacemakers, cardiac resynchronization therapy (CRT), wearable monitoring devices, and digital rhythm management. Leading experts will discuss guideline-directed management, advances in atrial fibrillation treatment, inherited arrhythmia syndromes, sudden cardiac death prevention, and emerging technologies that enhance diagnostic precision and therapeutic success. The session encourages interdisciplinary collaboration among electrophysiologists, cardiologists, biomedical engineers, researchers, and healthcare professionals committed to advancing cardiac rhythm care

Coronary artery disease (CAD) remains the leading cause of cardiovascular mortality worldwide and continues to present significant clinical and public health challenges. Characterized by progressive narrowing of the coronary arteries due to atherosclerosis, CAD can result in myocardial ischemia, angina, myocardial infarction, heart failure, and sudden cardiac death. Advances in cardiovascular imaging, intravascular diagnostics, biomarker discovery, and personalized medicine have enhanced early diagnosis and improved risk assessment. Modern management strategies combine lifestyle modification, pharmacological therapy, percutaneous coronary intervention, coronary artery bypass surgery, and secondary prevention measures to optimize long-term cardiovascular health.

This session will focus on contemporary approaches to the prevention, diagnosis, and treatment of coronary artery disease. Topics include coronary physiology, advanced imaging techniques, complex coronary interventions, plaque characterization, lipid management, secondary prevention, novel pharmacotherapies, and evidence-based clinical guidelines. Experts will present findings from recent clinical trials, translational research, and emerging technologies that are transforming coronary care. Participants will gain valuable insights into individualized treatment strategies, multidisciplinary patient management, and future innovations aimed at reducing the global burden of coronary artery disease.

Structural heart disease encompasses a broad range of congenital and acquired abnormalities affecting the cardiac valves, chambers, septa, and great vessels. Advances in cardiovascular imaging, transcatheter interventions, and minimally invasive procedures have transformed the diagnosis and treatment of structural heart disorders, providing safer alternatives to traditional open-heart surgery for many patients. Multidisciplinary heart teams now integrate echocardiography, cardiac CT, MRI, and advanced procedural planning to optimize patient selection and improve procedural outcomes. Technological innovations continue to expand treatment options for complex structural abnormalities while enhancing procedural precision and patient safety.

This session will showcase current advances in structural heart disease management, including transcatheter valve replacement and repair, left atrial appendage closure, septal defect interventions, structural imaging, patient selection, procedural planning, and long-term clinical outcomes. Experts will present innovative devices, emerging interventional techniques, artificial intelligence applications, and evidence from recent clinical studies that are shaping the future of structural heart care. Discussions will emphasize multidisciplinary collaboration, personalized treatment strategies, and ongoing innovations that continue to improve quality of life and survival for patients  with structural  heart disease

Advanced cardiac imaging has become an essential component of modern cardiovascular medicine, providing accurate, non-invasive assessment of cardiac structure, function, and hemodynamics. Echocardiography remains the cornerstone of cardiovascular diagnosis, while cardiac computed tomography (CT), magnetic resonance imaging (MRI), nuclear cardiology, and hybrid imaging continue to expand diagnostic capabilities. Recent technological advances including three-dimensional imaging, strain analysis, artificial intelligence-assisted interpretation, and fusion imaging have improved diagnostic precision and enabled earlier detection of cardiovascular abnormalities. These modalities play a crucial role in evaluating coronary artery disease, heart failure, valvular disorders, congenital heart disease, cardiomyopathies, and structural heart interventions.

This session will examine recent developments in cardiovascular imaging technologies, emphasizing multimodality imaging, quantitative echocardiography, cardiac CT angiography, cardiac MRI, nuclear imaging, and emerging artificial intelligence applications. Experts will discuss clinical indications, imaging-guided interventions, diagnostic accuracy, risk stratification, and integration of imaging into personalized patient care. Participants will gain valuable insights into evolving imaging protocols, innovative technologies, clinical research, and future directions that continue to transform cardiovascular diagnosis and therapeutic decision-making.

Pediatric and congenital heart disease represents one of the most specialized areas of cardiovascular medicine, encompassing structural and functional abnormalities present at birth as well as acquired cardiovascular disorders affecting children and adolescents. Advances in prenatal diagnosis, neonatal intensive care, pediatric cardiac surgery, catheter-based interventions, and lifelong follow-up have dramatically improved survival rates and quality of life for children born with congenital heart defects. Modern care emphasizes early diagnosis, multidisciplinary collaboration, genetic evaluation, advanced imaging, and individualized treatment strategies that support patients throughout childhood and adulthood. Continued research is expanding our understanding of congenital heart development, long-term outcomes, and innovative therapeutic approaches.

This session will highlight current advances in pediatric cardiology and congenital heart disease, including fetal cardiology, congenital cardiac surgery, interventional procedures, genetic disorders, pediatric heart failure, pulmonary hypertension, and transition to adult congenital heart care. Experts will present emerging research, novel surgical techniques, advanced imaging applications, and evidence-based management strategies designed to improve patient outcomes. Discussions will focus on multidisciplinary care models, technological innovations, and global initiatives aimed at advancing pediatric cardiovascular health and reducing the burden of congenital heart disease worldwide

Hypertension remains the leading modifiable risk factor for cardiovascular disease and contributes significantly to stroke, heart failure, chronic kidney disease, peripheral vascular disease, and premature mortality. Despite advances in diagnosis and treatment, uncontrolled hypertension continues to affect millions of individuals worldwide. Vascular medicine complements hypertension management by addressing disorders affecting arteries, veins, and microvascular circulation through comprehensive diagnostic evaluation and evidence-based therapies. Recent innovations in ambulatory blood pressure monitoring, vascular imaging, precision medicine, lifestyle interventions, and digital health technologies are improving cardiovascular risk assessment and long-term disease management.

This session will explore advances in hypertension management, vascular biology, endothelial dysfunction, arterial stiffness, peripheral arterial disease, aortic disorders, and emerging therapeutic strategies. Experts will discuss international hypertension guidelines, resistant hypertension, novel antihypertensive agents, catheter-based therapies, cardiovascular prevention, and multidisciplinary approaches to vascular health. Participants will gain valuable insights into clinical research, technological innovations, and personalized treatment strategies that improve vascular function, reduce cardiovascular risk, and enhance long-term patient outcomes.

Cardiovascular pharmacology plays a central role in preventing, treating, and managing cardiovascular diseases through evidence-based medical therapies. Continuous advances in pharmacological research have introduced innovative medications that improve survival, reduce hospitalizations, and enhance quality of life for patients with heart failure, coronary artery disease, hypertension, arrhythmias, and thromboembolic disorders. Emerging therapeutic approaches increasingly incorporate pharmacogenomics, precision medicine, novel biologic agents, lipid-lowering therapies, anticoagulants, and anti-inflammatory drugs to optimize treatment outcomes. Understanding drug mechanisms, safety profiles, interactions, and individualized dosing remains essential for effective cardiovascular care.

This session will provide comprehensive insights into the latest developments in cardiovascular pharmacology, including heart failure therapeutics, antiplatelet and anticoagulant therapy, lipid-lowering agents, antihypertensive medications, antiarrhythmic drugs, precision pharmacotherapy, and emerging cardiovascular drug development. Experts will present findings from clinical trials, translational research, pharmacogenomic studies, and real-world evidence supporting innovative treatment strategies. Discussions will emphasize medication safety, personalized prescribing, evidence-based clinical practice, and future directions in cardiovascular drug discovery aimed at improving patient outcomes across diverse cardiovascular conditions.

Lipid disorders and atherosclerosis are among the primary contributors to cardiovascular disease, significantly increasing the risk of coronary artery disease, stroke, peripheral artery disease, and myocardial infarction. Dyslipidemia, characterized by elevated low-density lipoprotein (LDL) cholesterol, triglycerides, and reduced high-density lipoprotein (HDL) cholesterol, plays a central role in the development of atherosclerotic plaques and vascular inflammation. Recent advances in lipidomics, cardiovascular biomarkers, genetic testing, and imaging technologies have enhanced early detection and risk stratification, enabling clinicians to identify high-risk individuals before the onset of major cardiovascular events. Novel lipid-lowering therapies, including PCSK9 inhibitors, RNA-based therapeutics, and combination treatment strategies, are transforming cardiovascular prevention and long-term disease management.

This session will highlight current advances in lipid metabolism, atherosclerosis pathophysiology, preventive cardiology, and evidence-based lipid management. Experts will discuss emerging pharmacological therapies, international cholesterol guidelines, cardiovascular risk assessment, inflammation in atherosclerosis, precision medicine, and innovative approaches to reducing residual cardiovascular risk. Participants will gain valuable insights into clinical trials, translational research, and multidisciplinary treatment strategies aimed at improving cardiovascular outcomes through effective lipid control and comprehensive prevention of atherosclerotic cardiovascular disease.

Cardio-oncology is an emerging multidisciplinary specialty dedicated to preventing, detecting, and managing cardiovascular complications associated with cancer therapies. Advances in cancer treatment have significantly improved patient survival; however, many chemotherapeutic agents, targeted therapies, immunotherapies, and radiation treatments may adversely affect cardiovascular function, increasing the risk of heart failure, arrhythmias, hypertension, thromboembolism, and cardiomyopathy. Early cardiovascular assessment, risk stratification, and continuous monitoring are essential for minimizing treatment-related cardiac toxicity while ensuring optimal cancer care. Collaboration between oncologists, cardiologists, radiologists, and healthcare professionals has become increasingly important in delivering personalized and comprehensive patient management.

This session will explore recent developments in cardio-oncology, including cardiotoxicity prevention, cardiovascular imaging, biomarkers, precision medicine, long-term survivorship care, and evidence-based management strategies. Experts will present clinical guidelines, innovative diagnostic tools, cardioprotective therapies, and multidisciplinary care models that support both cardiovascular health and effective cancer treatment. Discussions will also address emerging research, clinical trials, digital health technologies, and future directions that continue to advance the rapidly evolving field of cardio-oncology.

Cardiovascular disease remains the leading cause of mortality among women worldwide, yet significant differences in disease presentation, diagnosis, treatment, and outcomes continue to exist compared with men. Hormonal influences, pregnancy-related complications, autoimmune disorders, menopause, and sex-specific risk factors contribute to the unique cardiovascular profile observed in women. Despite increasing awareness, cardiovascular disease in women is frequently underdiagnosed or diagnosed later, emphasizing the need for improved education, early risk assessment, and gender-specific preventive strategies. Advances in cardiovascular research are expanding our understanding of sex-related differences in disease mechanisms, clinical presentation, and therapeutic responses.

This session will focus on the prevention, diagnosis, and management of cardiovascular disease across all stages of a woman's life. Topics include ischemic heart disease, pregnancy-associated cardiovascular disorders, hypertension, heart failure, menopause, cardiovascular risk assessment, preventive cardiology, and personalized treatment approaches. Experts will discuss current clinical guidelines, emerging research, digital health innovations, and multidisciplinary strategies aimed at improving cardiovascular outcomes for women. The session provides an important platform for advancing gender-specific cardiovascular research and promoting equitable cardiovascular care worldwide

Artificial intelligence (AI) and digital health technologies are transforming cardiovascular medicine by enabling earlier diagnosis, predictive analytics, personalized treatment planning, and continuous patient monitoring. Machine learning algorithms, wearable devices, mobile health applications, telecardiology platforms, and remote monitoring systems are enhancing clinical decision-making while improving patient engagement and healthcare accessibility. AI-assisted interpretation of electrocardiograms, echocardiography, cardiac imaging, and clinical data is increasing diagnostic accuracy, optimizing workflow efficiency, and supporting precision cardiovascular care. These innovations are reshaping how clinicians detect cardiovascular disease, manage chronic conditions, and deliver patient-centered healthcare.

This session will explore the latest advances in artificial intelligence, digital cardiology, telemedicine, wearable technologies, remote patient monitoring, big data analytics, and clinical decision support systems. Experts will discuss AI applications in cardiovascular imaging, predictive modeling, risk stratification, population health management, cybersecurity, ethical considerations, and regulatory challenges associated with digital healthcare. Participants will gain valuable insights into emerging technologies, clinical implementation, ongoing research, and future innovations that continue to redefine cardiovascular diagnosis, treatment, and disease prevention.

Advances in cardiovascular genetics and precision medicine are transforming the diagnosis and management of inherited and acquired cardiovascular diseases. Genetic sequencing, genomic profiling, molecular diagnostics, and pharmacogenomics have improved our understanding of the genetic basis of cardiomyopathies, arrhythmias, congenital heart disease, familial hypercholesterolemia, and other inherited cardiovascular disorders. Precision medicine integrates genetic information with clinical, environmental, and lifestyle factors to develop individualized prevention strategies and targeted therapies. As genomic technologies become increasingly accessible, personalized cardiovascular care is becoming an integral component of modern clinical practice.

This session will examine the latest developments in cardiovascular genomics, genetic screening, molecular diagnostics, pharmacogenomics, biomarker discovery, and individualized treatment strategies. Experts will discuss emerging research, ethical considerations, genetic counseling, translational medicine, and innovative therapeutic approaches designed to improve patient outcomes. The session will also highlight the role of artificial intelligence, multi-omics technologies, and precision diagnostics in advancing personalized cardiovascular medicine and shaping the future of cardiovascular healthcare

Regenerative medicine and stem cell therapy represent a transformative frontier in cardiovascular research, offering innovative approaches to repair damaged heart tissue and restore cardiac function. Cardiovascular diseases often result in irreversible loss of cardiomyocytes following myocardial infarction or chronic heart failure, limiting the heart's natural ability to regenerate. Recent advances in stem cell biology, tissue engineering, biomaterials, gene editing, and regenerative therapeutics are creating new opportunities for cardiac repair and functional recovery. Researchers continue to investigate the therapeutic potential of mesenchymal stem cells, induced pluripotent stem cells, extracellular vesicles, and engineered cardiac tissues to improve myocardial regeneration and vascular repair while reducing fibrosis and inflammation.

This session will explore the latest developments in regenerative cardiovascular medicine, including stem cell therapies, cardiac tissue engineering, gene therapy, biomaterial scaffolds, translational research, and clinical applications. Experts will discuss ongoing clinical trials, mechanisms of cardiac regeneration, regulatory challenges, personalized regenerative therapies, and emerging technologies designed to improve long-term cardiovascular outcomes. The session provides a collaborative platform for clinicians, scientists, biomedical engineers, and industry leaders to exchange knowledge and accelerate the development of next-generation regenerative therapies for cardiovascular disease.